Conshohocken’s Cencora partnered with Curant Rare to help rare disease treatments reach patients faster and more smoothly, the companies announced in a press release.

Curant Rare announced a strategic collaboration with Cencora to support pharmaceutical companies bringing rare disease therapies to market. Rare disease drugs often face added hurdles, including complex regulations and limited patient access. This partnership is designed to help clear those roadblocks.

The collaboration combines Cencora’s global pharmaceutical services, including logistics, safety monitoring, and market access support, with Curant Rare’s specialty pharmacy and patient engagement tools. Together, the two companies will offer a more connected path from drug development to patient care.

According to Curant Health CEO and co-founder Patrick Dunham, the goal is to improve access and speed, making sure treatments get to patients who need them most. The joint effort also gives drug makers better insight into patient experiences through real-world data and feedback.

Curant Rare focuses on personalized care for people with rare and ultra-rare conditions, helping improve treatment adherence and quality of life. With Cencora’s deep roots in Montgomery County and global reach, the partnership highlights the region’s growing role in shaping the future of healthcare.

To learn more about the collaboration between Cencora and Curant Rare, visit Business Wire.

Editor’s Note: This post was originally published on MONTCO.Today in January 2026.